<DOC>
	<DOCNO>NCT00002131</DOCNO>
	<brief_summary>To examine safety efficacy two dos vesnarinone patient AIDS-related Kaposi 's sarcoma .</brief_summary>
	<brief_title>A Pilot Study OPC-8212 ( Vesnarinone ) Persons With AIDS-Related Kaposi 's Sarcoma</brief_title>
	<detailed_description>Twenty-eight patient ( 14 per cohort ) receive daily vesnarinone one two dos . At least seven patient low dose must complete 2 week therapy subsequent patient enter high dose . Patients successfully complete 16 week treatment may receive maintenance therapy duration study ( approximately 12-18 month ) .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Vesnarinone</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Chemoprophylaxis Pneumocystis carinii , candida , mycobacteria . Acyclovir acute treatment herpes outbreaks . Concurrent Treatment : Allowed : Limited electronbeam radiation therapy nonmarker lesion treatment Kaposi 's sarcoma . Patients must : Documented HIV infection . Kaposi 's sarcoma . No current constitutional sign HIV disease AIDSdefining condition Kaposi 's sarcoma . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Active malignancy Kaposi 's sarcoma , cutaneous basal cell carcinoma , situ carcinoma cervix . Current significant cardiac disease anomaly ( include prolong QTC EKG ) . Abnormal cardiothoracic ratio chest xray . Concurrent Medication : Excluded : Antiretroviral agent , include ddI , ddC , AZT , d4T . Immunosuppressive agent . Investigational HIV drugs/therapies include vaccine ( except treatment IND approve indication ) . Other antiKaposi 's sarcoma/HIV drug . Corticosteroids ( topical ) . Biologic response modifier . Megestrol acetate . Agents know cause neutropenia . Trimethoprim/sulfamethoxazole excess 160 mg trimethoprim 800 mg sulfamethoxazole thrice weekly . Cytotoxic chemotherapy . Concurrent Treatment : Excluded : Radiation therapy include electron beam irradiation ( limited electronbeam radiation nonmarker lesion treatment Kaposi 's sarcoma ) . Patients follow prior condition exclude : Prior history significant cardiac disease anomaly . History agranulocytosis severe grade 3 druginduced neutropenia documented abnormality granulocyte function . Prior Medication : Excluded : AZT within 14 day prior study entry . Acyclovir prophylaxis herpes within 48 hour prior study entry . Excluded within 30 day prior study entry : Interferon . Biologic response modifier . Cytotoxic chemotherapy . Prior Treatment : Excluded within 30 day prior study entry : Blood cellular blood product . Active illicit drug abuse ( specifically cocaine , amyl nitrate , heroin , cardioactive agent ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 1996</verification_date>
	<keyword>Sarcoma , Kaposi</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
	<keyword>vesnarinone</keyword>
</DOC>